| ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migration. | ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migration.
Kosinski J, Sechi A, Hain J, Villwock S, Ha SA, Hauschulz M, Rose M, Steib F, Ortiz-Brüchle N, Heij L, Maas SL, van der Vorst EPC, Knoesel T, Altendorf-Hofmann A, Simon R, Sauter G, Bednarsch J, Jonigk D, Dahl E., Free PMC Article | 06/18/2024 |
| The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells. | The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells.
Rose M, Noetzel E, Kistermann J, Eschenbruch J, Rushrush S, Gan L, Knüchel R, Gaisa NT, Dahl E., Free PMC Article | 11/13/2021 |
| ITIH5, a p53-responsive gene, inhibits the growth and metastasis of melanoma cells by downregulating the transcriptional activity of KLF4. | ITIH5, a p53-responsive gene, inhibits the growth and metastasis of melanoma cells by downregulating the transcriptional activity of KLF4.
Liu J, Cao F, Li X, Zhang L, Liu Z, Li X, Lin J, Han C., Free PMC Article | 10/16/2021 |
| Genetic effects on planum temporale asymmetry and their limited relevance to neurodevelopmental disorders, intelligence or educational attainment. | Genetic effects on planum temporale asymmetry and their limited relevance to neurodevelopmental disorders, intelligence or educational attainment.
Carrion-Castillo A, Pepe A, Kong XZ, Fisher SE, Mazoyer B, Tzourio-Mazoyer N, Crivello F, Francks C. | 07/10/2021 |
| Inter-alpha-Trypsin Inhibitor Heavy Chain 5 (ITIH5) Is a Natural Stabilizer of Hyaluronan That Modulates Biological Processes in the Skin. | Inter-α-Trypsin Inhibitor Heavy Chain 5 (ITIH5) Is a Natural Stabilizer of Hyaluronan That Modulates Biological Processes in the Skin.
Huth S, Huth L, Marquardt Y, Fietkau K, Dahl E, Esser PR, Martin SF, Heise R, Merk HF, Baron JM. | 07/10/2021 |
| Suppression of pancreatic cancer liver metastasis by secretion-deficient ITIH5. | Suppression of pancreatic cancer liver metastasis by secretion-deficient ITIH5.
Young ED, Manley SJ, Beadnell TC, Shearin AE, Sasaki K, Zimmerman R, Kauffman E, Vivian CJ, Parasuram A, Iwakuma T, Grandgenett PM, Hollingsworth MA, O'Neil M, Welch DR., Free PMC Article | 04/24/2021 |
| The results demonstrated that the MIR31HG-miR-31-ITIH5-PIK3CG pathway plays a role in the pathogenesis of Hirschsprung disease. | Aberrant expression of LncRNA-MIR31HG regulates cell migration and proliferation by affecting miR-31 and miR-31* in Hirschsprung's disease.
Cai P, Li H, Huo W, Zhu H, Xu C, Zang R, Lv W, Xia Y, Tang W. | 10/12/2019 |
| ITIH5 may represent a novel modulator of TGF-beta superfamily signaling. | ITIH5 induces a shift in TGF-β superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death.
Rose M, Meurer SK, Kloten V, Weiskirchen R, Denecke B, Antonopoulos W, Deckert M, Knüchel R, Dahl E. | 11/24/2018 |
| Results provide evidence that ITIH5 triggers a reprogramming of breast cancer cells through global epigenetic changes effecting DAPK1. ITIH5 may represent an ECM modulator in epithelial breast tissue mediating suppression of tumor initiating cancer cell characteristics which are thought being responsible for the metastasis of breast cancer. | ITIH5 mediates epigenetic reprogramming of breast cancer cells.
Rose M, Kloten V, Noetzel E, Gola L, Ehling J, Heide T, Meurer SK, Gaiko-Shcherbak A, Sechi AS, Huth S, Weiskirchen R, Klaas O, Antonopoulos W, Lin Q, Wagner W, Veeck J, Gremse F, Steitz J, Knüchel R, Dahl E., Free PMC Article | 02/10/2018 |
| Low ITIH5 expression is associated with liver metastasis in pancreatic cancer. | Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer.
Sasaki K, Kurahara H, Young ED, Natsugoe S, Ijichi A, Iwakuma T, Welch DR., Free PMC Article | 09/16/2017 |
| This is the first study so far showing a putative tumor suppressive function of ITIH5 in cervical carcinogenesis. | Gene expression analysis combined with functional genomics approach identifies ITIH5 as tumor suppressor gene in cervical carcinogenesis.
Dittmann J, Ziegfeld A, Jansen L, Gajda M, Kloten V, Dahl E, Runnebaum IB, Dürst M, Backsch C. | 09/9/2017 |
| The current study describes a novel mechanism linking the TSG-6 transfer of the newly described HC5 to the HA-dependent control of cell phenotype. The interaction of HC5 with cell surface HA was essential for TGFbeta1-dependent differentiation of fibroblasts to myofibroblasts, highlighting its importance as a novel potential therapeutic target. | Tumor Necrosis Factor-stimulated Gene 6 (TSG-6)-mediated Interactions with the Inter-α-inhibitor Heavy Chain 5 Facilitate Tumor Growth Factor β1 (TGFβ1)-dependent Fibroblast to Myofibroblast Differentiation.
Martin J, Midgley A, Meran S, Woods E, Bowen T, Phillips AO, Steadman R., Free PMC Article | 11/12/2016 |
| ITIH5 may be a novel putative tumor suppressor gene in NSCLC with a potential molecular significance in the squamoid ADC subtype and further clinical impact for risk stratification of adenocarcinoma patients. | Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
Dötsch MM, Kloten V, Schlensog M, Heide T, Braunschweig T, Veeck J, Petersen I, Knüchel R, Dahl E., Free PMC Article | 08/6/2016 |
| Hence, we can strengthen the presumption that ITIH5 may constitute a novel regulatory molecule of the human skin that could play an important role in in fl ammation via its interaction with hyaluronic acid. | Inter-α-trypsin inhibitor heavy chain 5 (ITIH5) is overexpressed in inflammatory skin diseases and affects epidermal morphology in constitutive knockout mice and murine 3D skin models.
Huth S, Heise R, Vetter-Kauczok CS, Skazik C, Marquardt Y, Czaja K, Knüchel R, Merk HF, Dahl E, Baron JM. | 06/11/2016 |
| ITIH5 expression is decreased in gastric cancer and that low expression of this protein is associated with poor clinical outcome. | Decreased ITIH5 expression is associated with poor prognosis in primary gastric cancer.
Mai C, Zhao JJ, Tang XF, Wang W, Pan K, Pan QZ, Zhang XF, Jiang SS, Zhao BW, Li YF, Xia JC, Zhou ZW. | 07/25/2015 |
| ITIH5 is a novel putative tumor suppressor gene in colon cancer with a potential impact in the CIMP-related pathway. | Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype.
Kloten V, Rose M, Kaspar S, von Stillfried S, Knüchel R, Dahl E., Free PMC Article | 05/16/2015 |
| Tumor-specific methylation of the three-gene panel (ITIH5, DKK3, and RASSF1A) might be a valuable biomarker for the early detection of breast cancer. | Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening.
Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, Veeck J, Hartmann A, Knüchel R, Dahl E., Free PMC Article | 03/21/2015 |
| provide evidence that down-regulation of ITIH5 by aberrant DNA hypermethylation may provoke invasive phenotypes in human bladder cancer | Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours.
Rose M, Gaisa NT, Antony P, Fiedler D, Heidenreich A, Otto W, Denzinger S, Bertz S, Hartmann A, Karl A, Knüchel R, Dahl E. | 05/17/2014 |
| ITIH5 gene expression is regulated both by obesity and by the region between visceral and subcutaneous adipose tissue. | Functional annotation of the human fat cell secretome.
Dahlman I, Elsen M, Tennagels N, Korn M, Brockmann B, Sell H, Eckel J, Arner P. | 10/13/2012 |
| ITIH-5 is highly expressed in sc adipose tissue, increased in obesity, down regulated after weight loss, and associated with measures of body size and metabolism. | ITIH-5 expression in human adipose tissue is increased in obesity.
Anveden Å, Sjöholm K, Jacobson P, Palsdottir V, Walley AJ, Froguel P, Al-Daghri N, McTernan PG, Mejhert N, Arner P, Sjöström L, Carlsson LM, Svensson PA. | 07/7/2012 |
| Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article | 06/30/2010 |
| Observational study and genome-wide association study of gene-disease association. (HuGE Navigator) | Genome-wide pleiotropy of osteoporosis-related phenotypes: the Framingham Study.
Karasik D, Hsu YH, Zhou Y, Cupples LA, Kiel DP, Demissie S., Free PMC Article | 04/7/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease.
Grupe A, Li Y, Rowland C, Nowotny P, Hinrichs AL, Smemo S, Kauwe JS, Maxwell TJ, Cherny S, Doil L, Tacey K, van Luchene R, Myers A, Wavrant-De Vrièze F, Kaleem M, Hollingworth P, Jehu L, Foy C, Archer N, Hamilton G, Holmans P, Morris CM, Catanese J, Sninsky J, White TJ, Powell J, Hardy J, O'Donovan M, Lovestone S, Jones L, Morris JC, Thal L, Owen M, Williams J, Goate A., Free PMC Article | 12/2/2009 |
| Both ITIH5 protein expression and ITIH5 promoter methylation may serve as prognostic biomarkers, thereby helping improve clinical patient outcome. | [Novel prognostic marker in invasive breast cancer. ITIH5 expression is abrogated by aberrant promoter methylation].
Veeck J, Breuer E, Rose M, Chorovicer M, Naami A, Bektas N, Alkaya S, von Serényi S, Horn F, Hartmann A, Knüchel R, Dahl E. | 01/21/2010 |
| Promoter methylation-mediated loss of ITIH5 expression is associated with unfavourable outcome in breast cancer patients. | The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Dürst M, Kristiansen G, Wild PJ, Hartmann A, Knuechel R, Dahl E. | 01/21/2010 |